Literature DB >> 55045

Large doses of glucocorticoid in the treatment of alopecia areata.

J L Burton, S Shuster.   

Abstract

Severe extensive alopecia areata (totalis) was treated with prednisolone as a single 2 g dose i.v. (22 patients) or 0.5 g daily for 5 days orally (13 patients). Four of the patients responded well, 12 had a poor response and 19 had no response. There was a relapse in some at about 6 months, which could be arrested by a further single i.v. dose, but the risks of this form of therapy are unclear and it cannot be recommended for general use. The clinical response to a single dose of corticosteroid implies, however, that there may be a 'switch' mechanism in certain auto-immune diseases, with an all-or-none response.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 55045

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  5 in total

1.  Medium-dose prednisolone pulse therapy in alopecia areata.

Authors:  Pinelopi Efentaki; Andreas Altenburg; Johannes Haerting; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-11

Review 2.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

3.  Alopecia areata.

Authors: 
Journal:  Br Med J       Date:  1979-02-24

4.  The effect of systemic prednisolone on arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous inflammation.

Authors:  A Kobza Black; M W Greaves; C N Hensby
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

5.  Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata.

Authors:  In Kwon Yeo; Eun Jung Ko; Yeon A No; Ee Seok Lim; Kui Young Park; Kapsok Li; Beom Joon Kim; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.